Trial Profile

Clinical Trial on the Tolerance and Pharmacokinetics of Recombinant Humanized Anti-PD-L1 Monoclonal Antibody MSB2311 Injection in the Treatment of Advanced Solid Tumor on Phase I

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MSB 2311 (Primary)
Indications Haematological malignancies; Lymphoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors MabSpace Biosciences

Most Recent Events

11 Dec 2023 Status changed from recruiting to completed.
08 Jun 2021 Updated results (n=33; data cutoff date Aug 31, 2020) assessing safety and efficacy of MSB2311 in patients with advanced solid tumors and hematological malignancies, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
19 May 2021 Results (n=33) presented in a Transcenta Holding Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com